5.78
price down icon0.34%   -0.02
after-market Dopo l'orario di chiusura: 5.79 0.010 +0.17%
loading

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

pulisher
05:23 AM

Is now a turning point for Vir Biotechnology Inc.Gold Moves & Short-Term Trading Alerts - newser.com

05:23 AM
pulisher
Oct 15, 2025

Is this a good reentry point in Vir Biotechnology Inc.2025 Trading Volume Trends & AI Driven Stock Reports - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Will Vir Biotechnology Inc. stock deliver consistent dividends2025 Major Catalysts & Real-Time Stock Entry Alerts - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Why Vir Biotechnology Inc. stock remains on watchlistsEarnings Recap Summary & Growth Focused Investment Plans - newser.com

Oct 14, 2025
pulisher
Oct 10, 2025

Endurance (Cayman) Ltd Svf Sells 466,242 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

What institutional flow reveals about Vir Biotechnology Inc.Stop Loss & Free Weekly Watchlist of Top Performers - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Study launches of VIR-5500 combined with ARPIs in mCRPC - Urology Times

Oct 10, 2025
pulisher
Oct 09, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTE - PharmiWeb.com

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology announces first patient dosed in part 3 of phase 1 trial - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology doses first patient in prostate cancer combo trial - Investing.com

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology (VIR) Advances Prostate Cancer Treatment with VIR-5500 Trial - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology stock rises as company doses first patient in prostate cancer trial - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology doses first patient in prostate cancer combo trial By Investing.com - Investing.com South Africa

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer - Business Wire

Oct 09, 2025
pulisher
Oct 09, 2025

Should You Allocate More Funds to DCX Systems Limited in YEARResistance Breakout Alerts & Accelerated Capital Growth - earlytimes.in

Oct 09, 2025
pulisher
Oct 09, 2025

Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? - Nasdaq

Oct 09, 2025
pulisher
Oct 08, 2025

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.7%Here's What Happened - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

What analysts say about Vir Biotechnology Inc stockInsider Trading Compliance & Exceptional Return Opportunities - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025 - BioSpace

Oct 08, 2025
pulisher
Oct 08, 2025

Vir Biotechnology to present hepatitis delta treatment results at liver meeting - Investing.com Canada

Oct 08, 2025
pulisher
Oct 07, 2025

Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $2,503,901.52 in Stock - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 73,955 Shares - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liv - PharmiWeb.com

Oct 07, 2025
pulisher
Oct 07, 2025

Vir Biotechnology to present hepatitis delta treatment results at liver meeting By Investing.com - Investing.com South Africa

Oct 07, 2025
pulisher
Oct 07, 2025

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting - Business Wire

Oct 07, 2025
pulisher
Oct 06, 2025

Using AI based signals to follow Vir Biotechnology Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Price momentum metrics for Vir Biotechnology Inc. explainedWeekly Trade Analysis & Safe Entry Point Identification - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Is Vir Biotechnology Inc. a candidate for recovery playPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Clarius Group LLC Purchases 560,342 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat

Oct 05, 2025
pulisher
Oct 04, 2025

NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World

Oct 04, 2025
pulisher
Oct 02, 2025

Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus

Oct 02, 2025
pulisher
Oct 02, 2025

Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat

Oct 02, 2025
pulisher
Oct 01, 2025

KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 S - PharmiWeb.com

Oct 01, 2025
pulisher
Oct 01, 2025

Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025 - GlobeNewswire

Oct 01, 2025
pulisher
Sep 28, 2025

Can machine learning forecast Vir Biotechnology Inc. recoveryWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Vir Biotechnology Shares Rise After Upgrade From BofA Securities - 富途牛牛

Sep 28, 2025
pulisher
Sep 23, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 23, 2025
pulisher
Sep 21, 2025

Gains Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Short Interest & Entry and Exit Point Strategies - خودرو بانک

Sep 21, 2025
pulisher
Sep 20, 2025

Earnings Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Trade Ideas & High Return Trade Opportunity Guides - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Goldman Sachs Group Inc. Boosts Holdings in Vir Biotechnology, Inc. $VIR - MarketBeat

Sep 20, 2025
$37.01
price up icon 1.84%
$87.57
price up icon 0.30%
$33.17
price up icon 1.28%
$105.14
price up icon 0.06%
biotechnology ONC
$316.42
price down icon 0.50%
$165.76
price up icon 1.57%
Capitalizzazione:     |  Volume (24 ore):